CompletedNCT05539651Updated Dec 4, 2024

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

A Phase 1 interventional study of RBD5044 and Placebo in Health Volunteer, sponsored by Suzhou Ribo Life Science Co. Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Suzhou Ribo Life Science Co. Ltd. · Phase 1, Interventional, and Treatment

Phase: Phase 1
Study type: Interventional
Enrollment: 72
Allocation: Randomized
Ages: 18 Years to 65 Years
Sex: All

Study summary

This is a randomized, double-blind, placebo-controlled phase I study to evaluate the safety, tolerability, PK profiles and PD effect of single and multiple ascending doses of subcutaneously administered RBD5044 in healthy subjects. The study will be performed in 2 phases: single ascending dose (SAD) phase and multiple ascending doses (MAD) phase in healthy subjects. There are 6 cohorts in SAD phases, the dose levels are 5mg, 20mg, 60mg, 90mg, 120mg and 150mg. There are 3 cohorts in MAD phases, the dose levels are 60mg, 90mg and 120mg.The decision to escalate to subsequent dose levels will be made by the SRC based on the review of all available safety information, including AEs, ECGs, vital signs, and clinical laboratory test results in each cohort.

Conditions studied

Health Volunteer

In context

Lead sponsor

Suzhou Ribo Life Science Co. Ltd. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 65 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

A subject will be eligible for inclusion in this study only if all of the following criteria are met:

Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.
Male and female subjects, aged 18 to 65 years (inclusive).
Body mass index between 18 and 32 kg/m2, inclusive.
Fasting TG ≥ 0.9 mmol/L (80 mg/dL) and ≤ 3.4 mmol/L (300 mg/dL) at screening.
Fasting LDL-C \< 4.9 mmol/L (\<190 mg/dL) at screening.
Healthy as determined by pre-study medical history, physical examination, clinical laboratory assessments, and 12-lead electrocardiogram (ECG).
Satisfy one of the following:
- Females: must be non-pregnant and non-lactating; surgically sterile, post-menopausal, abstinent, or if engaged in sexual relations of child-bearing potential, the subject is using an acceptable contraceptive method (refer to Section 4.6.3) for four weeks before, during, and for at least 6 months after the last dose of study drug administration.
- Males: must be surgically sterile, abstinent, or if engaged in sexual relations of child-bearing potential, the subject is utilizing an acceptable contraceptive method (refer to Section 4.6.3)) during and for at least 6 months after the last dose of study drug administration.
Non-smokers and non-nicotine users for at least 90 days before screening

Exclusion criteria

Exclusion Criteria:

A subject meeting any of the following exclusion criteria will not be allowed to participate in this study:

Any uncontrolled or serious disease, or any medical or surgical condition, may interfere with participation in the clinical study and/or put the subject at significant risk (according to the investigator's judgment) if he/she participates in the clinical study.
History or presence of cardiovascular disease (including peripheral artery and cerebrovascular disease).
Systolic blood pressure (SBP) > 140 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg after 10 minutes of supine rest, unless determined by the investigator to be not clinically relevant.
Diagnosis of diabetes mellitus.
Received any medication or nutraceutical to alter serum lipids within 30 days before screening.
Active serious mental illness or psychiatric disorder, including but not limited to schizophrenia, bipolar disorder, or severe depression, which require current pharmacological intervention.
Alanine aminotransferase (ALT) and/or total bilirubin are above the upper limit of normal reference range (ULN); no investigator discretion and repeat assessments are allowed.
Aspartate aminotransferase (AST), alkaline phosphatase (ALP), or gamma-glutamyl transferase (GGT) > 2 × ULN (no investigator discretion); or, if AST, ALP, or GGT > ULN, but ≤ 2 × ULN and considered clinically relevant by the investigator.
Used prescription drugs within 14 days or 7 half-lives (whichever is longer) before the first dose of study drug.
Used over-the-counter medication, excluding routine vitamins, within 7 days before the first dose of the study drug, unless determined by the investigator to be not clinically relevant, and unlikely to impact blood lipids level.
Received an investigational product within 30 days or 7 half-lives (whichever is longer) before the first dose of the study drug or are in the follow-up of another clinical study. If subjects used advanced therapy (ASO/siRNA/gene therapy/cell therapy), it should be judged by the investigator.
Hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), syphilis infection, or positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCVAb), HIV antibody (HIVAb), treponema pallidum antibody (TP-Ab) at screening.
Clinically significant illness within 7 days before the first dose of the study drug.
Consume more than 14 (female) or 21 (male) units of alcohol per week (unit: 1 glass of wine [125 mL] = 1 measure of spirits = ½ pint of beer) within the 12 months before screening or positive screen for alcohol abuse.
History or clinical evidence of drug abuse within the 12 months before screening or positive screen for drug abuse. Drug abuse is defined as compulsive, repetitive, and/or chronic use of drugs or other substances with or without problems related to their use and/or where stopping or a dose reduction will lead to withdrawal symptoms.
Donated more than 500 mL of blood within 90 days before the first dose of the study drug.
History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-acetylgalactosamine (GalNAc).
History of intolerance to subcutaneous (SC) injection or relevant abdominal scarring (surgical, burns, etc.).
Any conditions which would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study in the opinion of the investigator.

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Sequential assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 72 participants (actual)

Study arms

Experimental
RBD5044 SAD experimental group
Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD5044 on Day 1.
Drug: RBD5044
Experimental
RBD5044 MAD experimental group
Subjects in MAD experimental groups will receive one subcutaneous injection of RBD5044 on Day 1 and another subcutaneous injection of RBD5044 on Day 29.
Drug: RBD5044
Placebo comparator
Placebo SAD group
Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.
Drug: Placebo
Placebo comparator
Placebo MAD group
Subjects in MAD placebo groups will receive one subcutaneous injection of placebo on Day 1 and another subcutaneous injection of placebo on Day 29.
Drug: Placebo

Interventions

DrugRBD5044
Subcutaneously Administered RBD5044 in Healthy Subjects
DrugPlacebo
Subcutaneously Administered Placebo in Healthy Subjects

What researchers measure

Primary outcomes

Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0
The investigator will make an assessment of intensity for each AE and SAE reported during the study according to CTCAE V5.0
Time frame: SAD: Up to 24 weeks; MAD: Up to 28 weeks

Secondary outcomes

To characterize the pharmacokinetic parameter Cmax of RBD5044 in healthy subjects
Plasma Maximum concentration (Cmax)
Time frame: SAD: within 60 minutes before dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after dosing; MAD: within 60 minutes before day 1 and day 29 dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after Day 1 and day 29 dosing
To characterize the pharmacokinetic parameter Tmax of RBD5044 in healthy subjects
Time to maximum concentration (Tmax)
Time frame: SAD: within 60 minutes before dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after dosing; MAD: within 60 minutes before day 1 and day 29 dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after Day 1 and day 29 dosing
To characterize the pharmacokinetic parameter AUC0-inf of RBD5044 in healthy subjects
Area under the concentration-time curve from 0 to infinity (inf) (AUC0-inf)
Time frame: SAD: within 60 minutes before dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after dosing; MAD: within 60 minutes before day 1 and day 29 dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after Day 1 and day 29 dosing
To characterize the pharmacokinetic parameter AUC0-t of RBD5044 in healthy subjects
Area under the concentration-time curve from 0 to the collection time t (AUC0-t)
Time frame: SAD: within 60 minutes before dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after dosing; MAD: within 60 minutes before day 1 and day 29 dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after Day 1 and day 29 dosing
To characterize the pharmacokinetic parameter t1/2 of RBD5044 in healthy subjects
Plasma Half-Life (t1/2)
Time frame: SAD: within 60 minutes before dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after dosing; MAD: within 60 minutes before day 1 and day 29 dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after Day 1 and day 29 dosing
To characterize the pharmacokinetic parameter λz of RBD5044 in healthy subjects
Terminal rate constant (λz)
Time frame: SAD: within 60 minutes before dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after dosing; MAD: within 60 minutes before day 1 and day 29 dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after Day 1 and day 29 dosing
To characterize the pharmacokinetic parameter MRT of RBD5044 in healthy subjects
mean residence time (MRT)
Time frame: SAD: within 60 minutes before dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after dosing; MAD: within 60 minutes before day 1 and day 29 dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after Day 1 and day 29 dosing
To characterize the pharmacokinetic parameter CL/F of RBD5044 in healthy subjects
Oral clearance (CL/F)
Time frame: SAD: within 60 minutes before dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after dosing; MAD: within 60 minutes before day 1 and day 29 dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after Day 1 and day 29 dosing
To characterize the pharmacokinetic parameter Vz/F of RBD5044 in healthy subjects
Volume of distribution in the terminal elimination period (Vz/F)
Time frame: SAD: within 60 minutes before dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after dosing; MAD: within 60 minutes before day 1 and day 29 dosing, and at 0.25, 0.5, 1, 2, 4, 6, 8,10,12, 24 and 48 hours after Day 1 and day 29 dosing
To evaluate the pharmacodynamics (PD) effect of RBD5044 on serum levels of APOC3 in healthy subjects
by testing Concentrations of APOC3
Time frame: SAD: Up to 24 weeks; MAD: Up to 28 weeks
To evaluate the PD effect of RBD5044 on serum levels of triglyceride (TG) in healthy subjects.
by testing Concentrations of TG
Time frame: SAD: Up to 24 weeks; MAD: Up to 28 weeks

Study locations

1 site

Q-Pharm Pty Limited
Brisbane, Australia

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05539651
Lead sponsor: Suzhou Ribo Life Science Co. Ltd.
Responsible party: Sponsor
First posted: Sep 14, 2022
Start date: Nov 10, 2022
Primary completion: Oct 30, 2024
Completion: Oct 30, 2024
Last update: Dec 4, 2024

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Suzhou Ribo Life Science Co. Ltd.

Start the discussion